In March 2022, the US Food and Drug Administration (FDA) approved the LAG‐3 antibody relatlimab in combination with the PD‐1 antibody nivolumab for the treatment of advanced (unresectable stage III and stage IV) melanoma. This evidence concerns the gene PDCD1 and melanoma.